SIRT2 and metabolic dysfunction-associated steatotic liver disease: This reduction was also confirmed in HepG2 cells treated with palmitate in a time- and dose-dependent manner, indicating that hepatic sirt-2 expression significantly decreased in the context of NAFLD [78].